Discontinuation of immune checkpoint inhibitors for reasons other than disease progression and the impact on relapse and survival of advanced melanoma patients. A systematic review and meta-analysis.

Front Immunol · 2025 · PMC11825796 · PMID 39958328

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Risk of relapse did not reach statistical significance when anti-CTL4+anti-PD1 treatment was compared to anti-PD1 monotherapy (n=7, OR 1.29, 95%CI 0.69 – 2.41). 3.6.2.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.